The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Drugs to Reduce the Side Effects of Chemotherapy
Official Title: A Randomized, Double-Blind Trial to Compare the Clinical Efficacy and Safety of Granisetron vs. Metoclopramide Combined to Dexamethasone in the Prophylaxis of Chemotherapy-Induced Delayed Emesis
Study ID: NCT00003213
Brief Summary: RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients treated with chemotherapy. It is not known whether receiving dexamethasone with granisetron is more effective than receiving dexamethasone with metoclopramide for reducing the side effects of chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of dexamethasone with either granisetron or metoclopramide in patients treated with chemotherapy.
Detailed Description: OBJECTIVES: I. Compare the clinical efficacy and safety of Granisetron or Metoclopramide in combination with Dexamethasone in the prophylaxis of delayed nausea and vomiting induced by emetogenic cancer chemotherapy in patients with or without emesis in the acute phase. OUTLINE: This is a randomized, double blind study. Patients are stratified by prior chemotherapy (yes vs no), regular alcohol consumption (yes vs no), and prior chemotherapy regimen (cisplatin/carboplatin vs others). Patients receive dexamethasone and granisetron by mouth bid on day 0. Patients are then randomized to receive either granisetron or metoclopramide with dexamethasone concurrently with chemotherapy. Arm I: Patients receive granisetron by mouth bid on days 1-5. Dexamethasone and a placebo are administered by mouth once daily on days 1-5. Arm II: Patients receive metoclopramide by mouth tid on days 1-5. Dexamethasone is administered by mouth once daily on days 1-5. Patients must complete a diary card daily for 6 days. PROJECTED ACCRUAL: This study will accrue 360 patients.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Istituto Europeo Di Oncologia, Milano, , Italy
Kantonspital Aarau, Aarau, , Switzerland
Office of Walter Weber-Stadelman, Basel, , Switzerland
University Hospital, Basel, , Switzerland
Inselspital, Bern, Bern, , Switzerland
Hopital Cantonal Universitaire de Geneva, Geneva, , Switzerland
Istituto Oncologico della Svizzera Italiana, Lugano, , Switzerland
Burgerspital, Solothurn, Solothurn, , Switzerland
City Hospital Triemli, Zurich, , Switzerland
Klinik Hirslanden, Zurich, , Switzerland
Name: Matti S. Aapro, MD
Affiliation: European Institute of Oncology
Role: STUDY_CHAIR